Michael Kaseta

This profile gathers the share dealings of Michael Kaseta across 2 companies, led by Liquidia Corp and Heron Therapeutics, Inc. /DE/. The record holds 51 filings, for trades running from 10 November 2021 to 12 October 2026.

In open-market terms, that means 3 purchases worth €108k on one side and 10 sales worth €7.6M on the other. Sales outweigh purchases by €7.5M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 9 share grants and 29 option exercises. In 2026 alone, the filings show no purchases and 4 sales.

Half of the purchases are above €48k and half below. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 67% of cases, with a median move of +4.9%. This is a record of the past, not a forecast.

The record was last updated on 13 October 2026 with an option exercise in Liquidia Corp. The last purchase on record was published on 14 September 2022, which is 1,495 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.